Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Pipeline Review, H1 2016

  • ID: 3783269
  • Drug Pipelines
  • 41 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • ALSP, Inc.
  • BioMAS Ltd.
  • Phelix Therapeutics, LLC
  • Virobay Inc.
  • MORE
Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Pipeline Review, H1 2016

Summary

‘Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Pipeline Review, H1 2016’, provides in depth analysis on Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1)
- The report reviews Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • ALSP, Inc.
  • BioMAS Ltd.
  • Phelix Therapeutics, LLC
  • Virobay Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) Overview

Therapeutics Development

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Products under Development by Stage of Development

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Products under Development by Therapy Area

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Products under Development by Indication

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Pipeline Products Glance

Early Stage Products

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Products under Development by Companies

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Products under Development by Universities/Institutes

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Companies Involved in Therapeutics Development

ALSP, Inc.

BioMAS Ltd.

Oncomatryx Biopharma, S.L.

Phelix Therapeutics, LLC

Virobay Inc.

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Drug Profiles

ALP-496 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CIBP-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit Cathepsin B for Ebola Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMTX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAS - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Cathepsin B for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Cathepsin B for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-129 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-285 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-376 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBY-825 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Dormant Projects

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) - Featured News & Press Releases

Apr 19, 2016: American Life Science Pharmaceuticals Obtains Patent

Jan 25, 2016: ALSP invited to Give Oral Presentation at the Keystone TBI Conference January 25-27 in Santa Fe, New Mexico

Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by ALSP, Inc., H1 2016

Pipeline by BioMAS Ltd., H1 2016

Pipeline by Oncomatryx Biopharma, S.L., H1 2016

Pipeline by Phelix Therapeutics, LLC, H1 2016

Pipeline by Virobay Inc., H1 2016

Dormant Projects, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • ALSP, Inc.
  • BioMAS Ltd.
  • Phelix Therapeutics, LLC
  • Virobay Inc.
  • MORE
Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) pipeline Target constitutes close to 11 molecules. Out of which approximately 8 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Cathepsin B – Pipeline Review, H1 2016, outlays comprehensive information on the Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) Cathepsin B (CatB) is an enzymatic protein belonging to the peptidase. It promotes hydrolysis of proteins with broad specificity for peptide bonds. It cleaves -Arg-Arg-|-Xaa bonds in small molecule substrates. In addition to being an endopeptidase, shows peptidyl-dipeptidase activity, liberating C-terminal dipeptides. The molecules developed by Companies in Phase I, Phase 0, Preclinical and Discovery stages are 2, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Cathepsin B (APP Secretase or Cathepsin B1 or EC 3.4.22.1) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
ALSP, Inc.
BioMAS Ltd.
Oncomatryx Biopharma, S.L.
Phelix Therapeutics, LLC
Virobay Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll